Plain-English translation of NCT05753722 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This trial is testing a new drug called in adults with advanced or metastatic solid tumors. is designed to work by disabling a protein on tumor cells that creates a protective barrier—a barrier that normally prevents your immune cells from attacking the cancer. By breaking down this barrier, the medication may allow your body's T-cells to enter and fight the tumor more effectively.
Many advanced cancers are resistant to treatment because they develop physical barriers that block immune cells from reaching and attacking them. This medication aims to solve that problem by dismantling these barriers, potentially making both immunotherapy and other treatments more effective.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive the new medication either by itself or combined with (another immunotherapy drug), depending on which group you're assigned to. You'll attend regular study visits for safety monitoring and blood tests, and you'll have tumor biopsies taken before starting treatment and after some time on the medication to see how it's working. The trial is in its early phase, so researchers will start with lower doses and gradually increase them to find the safest and most effective dose.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States